NasdaqCM:NEOHealthcare
A Look At NeoGenomics (NEO) Valuation After The RaDaR ST Assay Launch
NeoGenomics (NEO) has drawn fresh attention after launching RaDaR ST, a circulating tumor DNA assay designed to detect molecular residual disease in blood using patient specific panels and advanced bioinformatics.
See our latest analysis for NeoGenomics.
Despite the RaDaR ST launch and recent earnings and guidance updates, NeoGenomics' 30 day share price return of 21.23% and year to date share price return of 19.22% both point to fading near term momentum. At the same time, the 5 year total...